Compare Sana Biotechnology Inc (SANA) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Sony Group Corp — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while Sony Group Corp trades at $23.55 (market cap $138.72B). The key difference: Sony Group Corp is far larger — about 134.7× Sana Biotechnology Inc's market cap, and Sony Group Corp pays a 0.67% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SONY | |
|---|---|---|
Market Cap | $1.03B | $138.72B |
Sector | Health | Technology |
52-Week High | $5.92 | $30.26 |
52-Week Low | $2.68 | $19.32 |
Enterprise Value | $946.04M | $136.57B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Sony's stock trades at $23.53, down 4.19% over 24 hours amid bearish technical signals. The company maintains strong operating cash flow of $2.32T for 2025 and beat earnings expectations in two of the last three quarters. However, negative net income margin of -1.75% and projected 2026 net loss of $221.6B raise concerns about near-term profitability despite analyst optimism.
The stock faces headwinds from technical weakness and projected earnings decline, but strong analyst support (68.75% buy ratings) and robust entertainment ecosystem provide long-term potential. Key risks include streaming competition and AI copyright litigation, while valuation metrics remain reasonable with P/E of 19.72 and EV/EBITDA of 7.71.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
